Davison S C, Hyman N, Prentis R A, Dehghan A, Chan K
Methods Find Exp Clin Pharmacol. 1980 Apr;2(2):77-82.
The synthesis of a series of pyridostigmine analogues wa reported. From these analogues N,N-dipropylcarbamoyloxy-1-methylpyridinium bromide was considered the most suitable compound for use as a common internal marker for the simultaneous determination of neostigmine and pyridostigmine in human plasma. The assay involved a preliminary ion-pair extraction of the drugs and the internal marker from plasma using potassium-iodide glycine buffer. The extract was analysed by a GC system (10% OV-17 on chromosorb W-AW, 100-120 mesh) linked to a nitrogensensitive detector. The calibration graphs of neostigmine and pyridostigmine were linear and reproducible over the range 5 ng to 100 ng per ml in 3 ml plasma samples. This assay procedure has been used to monitor simultaneously the plasma levels of neostigmine (4.7 to 33 ng per ml) and pyridostigmine (2.7 to 18.6 ng per ml) of a myasthenic patient over a period of twelve hours with repeated dosing of neostigmine bromide (30 mg) and pyridostigmine bromide (60 mg).
已报道了一系列吡啶斯的明类似物的合成。在这些类似物中，N,N-二丙基氨甲酰氧基-1-甲基吡啶溴化物被认为是用作同时测定人血浆中新斯的明和吡啶斯的明的常用内标物的最合适化合物。该测定法包括使用碘化钾甘氨酸缓冲液从血浆中对药物和内标物进行初步的离子对萃取。提取物通过与氮敏感检测器相连的气相色谱系统（在Chromosorb W-AW上涂有10% OV-17，100 - 120目）进行分析。在3 ml血浆样品中，新斯的明和吡啶斯的明的校准曲线在每毫升5 ng至100 ng的范围内呈线性且可重复。该测定程序已用于在12小时内对一名重症肌无力患者重复给予溴新斯的明（30 mg）和溴吡啶斯的明（60 mg）的情况下，同时监测其血浆中新斯的明（每毫升4.7至33 ng）和吡啶斯的明（每毫升2.7至18.6 ng）的水平。
